Cite

HARVARD Citation

    Roboz, G. et al. (2018). Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 124 (2), pp. 325-334. [Online]. 
  
Back to record